{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:08:31Z","timestamp":1765040911527,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jval.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T20:10:52Z","timestamp":1558037452000},"page":"854-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre"],"prefix":"10.1016","volume":"22","author":[{"given":"Lara","family":"Petelin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucinda","family":"Hossack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison H.","family":"Trainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.jval.2019.03.008_bib1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9","key":"10.1016\/j.jval.2019.03.008_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/gim.2017.231","article-title":"Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers","volume":"20","author":"Tuffaha","year":"2018","journal-title":"Genet Med"},{"year":"2013","series-title":"Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People With a Family History of Breast Cancer","key":"10.1016\/j.jval.2019.03.008_bib5"},{"issue":"4","key":"10.1016\/j.jval.2019.03.008_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/M13-1684","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: a systematic review to update the U.S. Preventive Services Task Force recommendation","volume":"160","author":"Nelson","year":"2014","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1016\/j.jval.2019.03.008_bib7","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jval.2019.03.008_bib8","first-page":"CD002748","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.jval.2019.03.008_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-148-9-200805060-00007","article-title":"Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer","volume":"148","author":"Warner","year":"2008","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.jval.2019.03.008_bib10","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/ijc.29534","article-title":"Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)","volume":"137","author":"Saadatmand","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-013-2540-z","article-title":"Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program","volume":"139","author":"Moller","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"10.1016\/j.jval.2019.03.008_bib12","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrclinonc.2015.173","article-title":"Population genetic testing for cancer susceptibility: founder mutations to genomes","volume":"13","author":"Foulkes","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.jval.2019.03.008_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jval.2017.12.022","article-title":"Personalized mammography screening and screening adherence\u2014a simulation and economic evaluation","volume":"21","author":"Arnold","year":"2018","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2019.03.008_bib15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/jmg.2009.072728","article-title":"The carrier clinic: an evaluation\u00a0of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2\u00a0carriers\u2014implications for oncogenetics practice","volume":"47","author":"Bancroft","year":"2010","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.jval.2019.03.008_bib16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s10897-017-0187-3","article-title":"Evaluation of breast cancer patients\u00a0with genetic risk in a university hospital: before and after the\u00a0implementation of a heredofamilial cancer unit","volume":"27","author":"Lobo","year":"2018","journal-title":"J\u00a0Genet Couns"},{"issue":"3","key":"10.1016\/j.jval.2019.03.008_bib17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10689-010-9333-x","article-title":"Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1\/2 carriers","volume":"9","author":"Pichert","year":"2010","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.jval.2019.03.008_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10549-016-3748-5","article-title":"Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany","volume":"156","author":"Vetter","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.jval.2019.03.008_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ygyno.2013.12.014","article-title":"Risk management options elected by women after testing positive for a BRCA mutation","volume":"132","author":"Garcia","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.jval.2019.03.008_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10689-006-0006-8","article-title":"Screening behavior in women at increased familial risk for breast cancer","volume":"5","author":"Antill","year":"2006","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.jval.2019.03.008_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s10897-018-0224-x","article-title":"An iPhone application intervention to promote surveillance among women with a BRCA mutation: pre-intervention data","volume":"27","author":"Cohen","year":"2018","journal-title":"J\u00a0Genet Couns"},{"issue":"10","key":"10.1016\/j.jval.2019.03.008_bib22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/gim.2017.255","article-title":"Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1\/2 mutation carriers: a systematic review","volume":"20","author":"Petelin","year":"2018","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.jval.2019.03.008_bib23","doi-asserted-by":"crossref","first-page":"e1000114","DOI":"10.1371\/journal.pmed.1000114","article-title":"The preclinical natural history of serous ovarian cancer: defining the target for early detection","volume":"6","author":"Brown","year":"2009","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.jval.2019.03.008_bib24","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1055-9965.EPI-11-1196","article-title":"Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined","volume":"21","author":"Heijnsdijk","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.jval.2019.03.008_bib25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Candido-dos-Reis","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.jval.2019.03.008_bib26","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-15-2750","article-title":"Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk\u2014combined results from two screening trials","volume":"23","author":"Skates","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jval.2019.03.008_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.jval.2019.03.008_bib28","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1471-0528.2011.02920.x","article-title":"Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status","volume":"118","author":"Manchanda","year":"2011","journal-title":"BJOG"},{"key":"10.1016\/j.jval.2019.03.008_bib30","unstructured":"Life tables, states, territories and Australia, 2011-2013, Catalogue no. 3302055001DO001. Australian Bureau of Statistics. www.abs.gov.au. Accessed April 27, 2016."},{"key":"10.1016\/j.jval.2019.03.008_bib31","doi-asserted-by":"crossref","first-page":"j372","DOI":"10.1136\/bmj.j372","article-title":"Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage","volume":"356","author":"Mytton","year":"2017","journal-title":"BMJ"},{"year":"2017","series-title":"Surveillance, Epidemiology, and End Results (SEER) program. SEER*Stat Database: Incidence\u2014SEER 18 Regs Research Data (1992-2014)","key":"10.1016\/j.jval.2019.03.008_bib32"},{"issue":"3","key":"10.1016\/j.jval.2019.03.008_bib33","doi-asserted-by":"crossref","first-page":"e0120189","DOI":"10.1371\/journal.pone.0120189","article-title":"Worse breast cancer prognosis of BRCA1\/BRCA2 mutation carriers: what\u2019s the evidence? A systematic review with meta-analysis","volume":"10","author":"van den Broek","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2010.33.0068","article-title":"Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study","volume":"30","author":"Goodwin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2019.03.008_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"issue":"9","key":"10.1016\/j.jval.2019.03.008_bib36","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1245\/s10434-015-4532-1","article-title":"Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis","volume":"22","author":"De Felice","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.jval.2019.03.008_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw177","article-title":"Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kotsopoulos","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.jval.2019.03.008_bib39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1148\/radiol.2017170458","article-title":"Influence of risk category and screening round on the performance of an MR imaging and mammography screening program in carriers of the BRCA mutation and other women at increased risk","volume":"286","author":"Vreemann","year":"2018","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.jval.2019.03.008_bib40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2019.03.008_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2015.11.009","article-title":"Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status","volume":"140","author":"Kotsopoulos","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.jval.2019.03.008_bib43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10549-014-2931-9","article-title":"MRI breast screening in high-risk women: cancer detection and survival analysis","volume":"145","author":"Evans","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.jval.2019.03.008_bib44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2019.03.008_bib45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40273-016-0410-3","article-title":"Unremarked or unperformed? Systematic review on reporting of validation efforts of health economic decision models in seasonal influenza and early breast cancer","volume":"34","author":"de Boer","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2019.03.008_bib46","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/bjc.2012.62","article-title":"Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis","volume":"106","author":"Verry","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib47","first-page":"23","article-title":"Comparison of treatment costs for breast cancer, by tumor stage and type of service","volume":"9","author":"Blumen","year":"2016","journal-title":"Am Health Drug Benefits"},{"issue":"3","key":"10.1016\/j.jval.2019.03.008_bib48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10689-017-0047-1","article-title":"Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations","volume":"17","author":"Kearton","year":"2018","journal-title":"Fam Cancer"},{"issue":"9","key":"10.1016\/j.jval.2019.03.008_bib49","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/ijc.23340","article-title":"International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","volume":"122","author":"Metcalfe","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jval.2019.03.008_bib50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.breast.2017.01.002","article-title":"Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history","volume":"32","author":"Skandarajah","year":"2017","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jval.2019.03.008_bib52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijc.30692","article-title":"The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2,991 patients and 1,043 controls by next-generation sequencing","volume":"141","author":"Lang","year":"2017","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.jval.2019.03.008_bib55","doi-asserted-by":"crossref","first-page":"e025317","DOI":"10.1136\/bmjopen-2018-025317","article-title":"Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol","volume":"8","author":"Dossa","year":"2018","journal-title":"BMJ Open"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519301779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301519301779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:16:10Z","timestamp":1761095770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301519301779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1098301519301779"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2019.03.008","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}